Brief: Vivoryon Therapeutics Q3 License Revenues At EUR 10.8 Mln

Vivoryon Therapeutics NV

04/11/2021 06:11

Nov 4 (Reuters) - VIVORYON THERAPEUTICS NV  05Y.F :
    * REPORTS Q3 2021 FINANCIAL RESULTS  AND HIGHLIGHTS
OPERATIONAL
PROGRESS
    * Q3 LICENSE REVENUES OF EUR 10.8 MILLION FROM A STRATEGIC
REGIONAL LICENSING PARTNERSHIP SIGNED WITH ITS PARTNER SIMCERE
ON JUNE 29, 2021 FOR GREATER CHINA
    * EXPECTS A CASH REACH UNTIL MID-2022
    * NET LOSS FOR NINE MONTHS ENDED SEPTEMBER 30, 2021 WAS EUR
7.3
MILLION, COMPARED TO EUR 12.2 MILLION FOR NINE MONTHS ENDED
SEPTEMBER 30, 2020

Source text for Eikon:  ID:nEQ1CymlFa 
Further company coverage:  05Y.F 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))